WEST LAFAYETTE, Ind., Feb. 17, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that the company will host a conference call on Monday, Feb. 24, at 8:30 a.m. EST to discuss its fourth quarter and full year 2013 financial results and provide an operational update.